Sirius Therapeutics
Advancing RNAi therapies globally to address significant cardiovascular risks
About Sirius Therapeutics
Sirius is a forward-thinking biotech company that is focused on creating new RNAi (RNA interference) therapies for international markets. RNAi is a biological process where RNA molecules inhibit gene expression, effectively "silencing" targeted genes. This technology is used by Sirius to develop innovative treatments for cardiovascular diseases.
The company has recently received approval from China's National Medical Products Administration (NMPA) to conduct human clinical trials for SRSD101, a siRNA (small interfering RNA) therapeutic for Dyslipidemia, a condition characterized by an abnormal amount of lipids in the blood. In addition, Sirius has submitted an application to begin the first clinical trial of Factor XI siRNA, a long-lasting, next-generation anticoagulant for Thromboembolic disorders, which are conditions caused by blood clots.
Sirius operates in the global biopharmaceutical market, serving patients in need of new treatment options. The company's business model revolves around the research, development, and commercialization of RNAi therapies. It generates revenue through the successful development and subsequent sale of these innovative therapies.
The company's investors include OrbiMed, Creacion Ventures, Hankang Capital, and Delos Capital, all of which are well-known institutional investors with extensive experience in the biopharmaceutical industry. The leadership team at Sirius is made up of industry veterans who have held senior positions at multinational pharmaceutical companies such as Pfizer, AstraZeneca, Novartis, Arrowhead, Dicerna, and ONYX.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2025 | $50M | $300M | OrbiMed · Creacion Ventures · BioTrack Capital · Hankang Capital | ↗ |
| SERIES BOther financing | Oct 2023 | $60M | $240M | Hongyuan Capital · Hankang Capital · OrbiMed · Delos Capital | ↗ |
Growth signals
Latest recorded traffic for Sirius Therapeutics is 3K monthly website visits, up 11.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Sirius Therapeutics in the San Diego ecosystem
The Sirius Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Hankang Capital- HCHongyuan Capital
OrbiMed
Delos Capital
National Small and Medium Enterprise Development- KFKangxi Global Investment Fund
- CVCreacion Ventures
BioTrack Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sirius Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sirius Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










